Nonthermal plasma as part of a novel strategy for vaccination

Mohamed, Hager; Esposito, R; Kutzler, Michele A.; Wigdahl, Brian; Krebs, Fred C.; Miller, Vandana

doi:10.1002/ppap.202000051

Cited by 14 publications

(16 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Defense against a viral infection begins with the non-specific innate immune response followed by activation of the virus-specific adaptive immune response, which may be cell-mediated (T cell), or antibodymediated (B cell). Many common viral infections can be cleared by these host defense mechanisms before clinically apparent symptoms develop [40][41][42][43] (Figure 3).…”

Section: Resolution Of Viral Infection In the Mammalian Host Relies Omentioning

confidence: 99%

“…APCs display the digested viral peptides on their cell surface and migrate to local lymph nodes to present them to the adaptive immune cells (T and B cells) in order to produce a cell or antibody-mediated response, respectively. Both responses target the specific virus against which they are generated and usually have no effect against other types of viruses [40][41][42][43].…”

Section: Resolution Of Viral Infection In the Mammalian Host Relies Omentioning

confidence: 99%

See 1 more Smart Citation

Non-Thermal Plasma as a Novel Strategy for Treating or Preventing Viral Infection and Associated Disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

Pathogenic viruses cause many human, animal, and plant diseases that are associated with substantial morbidity, mortality and socio-economic impact. Although effective strategies for combatting virus transmission and associated disease are available, global outbreaks of viral pathogens such as the virus responsible for the COVID-19 pandemic demonstrate that there is still a critical need for new approaches that can be used to interrupt the chain of viral infection and mitigate virus-associated pathogenesis. Recent studies point to non-thermal plasma (NTP), a partly ionized gas comprised of a complex mixture of reactive oxygen and nitrogen species along with physical effectors, as the potential foundation for new antiviral approaches. A more thorough understanding of the antiviral properties and safety of NTP has stimulated explorations of NTP as the basis for treatments of viral diseases. The recently described immunomodulatory properties of NTP are also being evaluated for potential use in immunotherapies of viral diseases as well as in antiviral vaccination strategies. In this review, we present the current state-of-the-art in addition to compelling arguments that NTP merits further exploration for use in the prevention and management of viral infections and associated diseases.

show abstract

Section: Resolution Of Viral Infection In the Mammalian Host Relies Omentioning

confidence: 99%

Section: Resolution Of Viral Infection In the Mammalian Host Relies Omentioning

confidence: 99%

Non-Thermal Plasma as a Novel Strategy for Treating or Preventing Viral Infection and Associated Disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most important DAMPs released from cancer cells during ICD are calreticulin, adenosine triphosphate (ATP), heat-shock proteins, and high mobility group protein B1 (HMGB1). DAMPs are a potent adjuvant for antigen-presenting cells (APCs), especially dendritic cells (DCs), inducing their migration to the regional lymphoid tissue, maturation, and stimulation of a specific anti-tumor immune response [ 14 ]. DCs are specialized APCs playing a key role in the initiation and regulation of innate and adaptive immune responses.…”

Section: Introductionmentioning

confidence: 99%

“…Optimization of DC vaccines implies the use of better protocols for preparing tumor antigens, designing new strategies for antigen loading, as well as selection of optimal adjuvants and maturation stimuli. In this context, the use of lysates from tumor cells subjected to ICD could be beneficial, as already well documented [ 14 , 18 , 19 , 20 ]. PAM treatment of tumor cells has not been explored up to the date for the stimulation of MoDCs.…”

Section: Introductionmentioning

confidence: 99%

Plasma-Activated Medium Potentiates the Immunogenicity of Tumor Cell Lysates for Dendritic Cell-Based Cancer Vaccines

Tomić

Petrović

Puаč

et al. 2021

Cancers

View full text Add to dashboard Cite

Autologous dendritic cells (DCs)-based vaccines are considered quite promising for cancer immunotherapy due to their exquisite potential to induce tumor antigen-specific cytotoxic T cells. However, a lack of efficient protocols for inducing immunogenic tumor antigens limits the efficacy of DC-based cancer vaccines. Here, we found that a plasma-activated medium (PAM) induces immunogenic cell death (ICD) in tumor cells but not in an immortalized L929 cell line or human peripheral blood mononuclear cells. PAM induced an accumulation of reactive oxygen species (ROS), autophagy, apoptosis, and necrosis in a concentration-dependent manner. The tumor lysates prepared after PAM treatment displayed increased immunogenicity in a model of human monocyte-derived DCs, compared to the lysates prepared by a standard freezing/thawing method. Mature DCs loaded with PAM lysates showed an increased maturation potential, as estimated by their increased expression of CD83, CD86, CD40, IL-12/IL-10 production, and attenuated PDL1 and ILT-4 expression, compared to the DCs treated with control tumor lysates. Moreover, in co-culture with allogeneic T cells, DCs loaded with PAM-lysates increased the proportion of cytotoxic IFN-γ+ granzyme A+ CD8+ T cells and IL-17A-producing T cells and preserved the Th1 response. In contrast, control tumor lysates-treated DCs increased the frequency of Th2 (CD4+IL-4+), CD4, and CD8 regulatory T cell subtypes, none of which was observed with DCs loaded with PAM-lysates. Cumulatively, these results suggest that the novel method for preparing immunogenic tumor lysates with PAM could be suitable for improved DC-based immunotherapy of cancer patients.

show abstract

“…One of the most exciting recent finding in CAP treatments in Oncology is that plasma treatments on cancer cells, beside other effects, indeed can stimulate the expression of markers that induce the immunogenic cell death via the activation of innate immune system of the host. [ 12 ] Pieces of evidence of the efficacy of nonthermal plasmas as immunogenic cell death inducers are discussed in the review by Mohamed et al, [ 13 ] where the fascinating hypothesis of vaccinating people against cancer is discussed, as well as in the expert opinion paper by Witzke et al [ 14 ]…”

mentioning

confidence: 99%